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Age and sex are risk factors of Alzheimer’s disease (AD). Among the neurotransmitter systems, gamma-
aminobutyric acid (GABA) has been implicated in AD pathogenesis but the relevance of sex-specific
GABAergic dysfunction during AD progression remains unknown. In the present study, we utilized
state-of-the-art high-resolution magic angle spinning nuclear magnetic resonance to systematically
monitor the brain region-, age-, and sex-specific modulation of GABA levels in wild-type and Tg2576
mice with amyloid pathology. In addition, we followed the possible role of reactive astrocytes in
sex-specific GABA modulation. In female Tg2576 mice, hippocampal GABA levels were significantly
elevated, along with higher number of reactive astrocytes and amyloid deposition. The elevated GABA
was found to be produced via the monoamine oxidase-B route from putrescine in reactive astrocytes,
more substantially in female than male mice, thus suggesting a role of astrocytes in memory impairment
and sex-related differences in AD. Our results paint a coherent model of memory impairment in AD and
signify that dynamic changes in regional GABA may be at the root of marked sex disparities observed in
AD.
 2017 Elsevier Inc. All rights reserved.1. Introduction
Alzheimer’s disease is a progressive neurodegenerative disease
characterized by impairment of memory and other cognitive
functions. The pathological hallmarks of Alzheimer’s disease
include widespread neuronal degeneration and the formation of
extracellular senile plaques and intracellular neurofibrillary tangles
(Price et al., 1991; Terry et al., 1991). Synaptic dysfunction induced
by b-amyloid (Ab) oligomer toxicity starts many years before the
clinical onset of Alzheimer’s disease and has been implicated in
cognitive decline (Canter et al., 2016; Dulla et al., 2016).
Gamma-aminobutyric acid (GABA) is the major inhibitory
neurotransmitter in the central nervous system (Li et al., 2016).
Maintaining a proper dynamic balance between the excitatory
glutamate (Glu) and inhibitory GABA neurotransmitters is criticalhemistry, Leiden University,
þ3171 527 4623; fax: þ3171
lia.aliamatysik@medizin.uni-
ll rights reserved.for neuronal function (Lehmann et al., 2012). Altered synaptic
balance was found to be one of the pathological factors that
contribute to Alzheimer’s disease (Canter et al., 2016; Dulla et al.,
2016; Sun et al., 2009). Recent evidence indicates that a disrupted
default neuronal network underlies impaired memory and that
alterations of GABAergic circuits may contribute to Alzheimer’s
disease by disrupting the overall network function (Jucker and
Walker, 2011; Li et al., 2016). Findings of GABAergic alterations in
Alzheimer’s disease are very conflicting. Early postmortem studies
in human brain or in animal models have reported that GABAergic
neurons and receptors are resistant to Alzheimer’s disease pathol-
ogy (Li et al., 2016; Lowe et al., 1988; Pike and Cotman, 1993; Rossor
et al., 1982; Spillane et al., 1977). However, several recent publica-
tions demonstrate that GABAergic neurotransmission undergoes
profound pathological changes in Alzheimer’s disease (Ramos et al.,
2006; Takahashi et al., 2010). In the temporal cortex of Alzheimer’s
disease patients, significantly lower levels of GABA were observed,
indicating deficient synaptic function and neuronal transmission
(Gueli and Taibi, 2013). The decreased GABA neurotransmitter
levels were also observed in the cerebrospinal fluid of Alzheimer’s
disease patients and cognitively normal humans with aging
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contrast to these reports, elevated GABA levels in hippocampus and
cerebrospinal fluid were reported in Alzheimer’s disease patients
and related to impaired synaptic plasticity, learning, and memory
(Jo et al., 2014; Samakashvili et al., 2011). Therefore, a common
agreement of GABA changes during Alzheimer’s disease progres-
sion remains to be settled, before exploring drugs to target
GABAergic neurotransmission as a potential therapy for
Alzheimer’s disease. The inconsistent and controversial results are
likely attributed by differences in the timing and duration of
experimental design, sex-specific and brain regionespecific differ-
ences in GABA and complex pattern of GABA changes during aging.
Many of the studies in animal models of Alzheimer’s disease
focused on predisease or early disease stages (Lalande et al., 2014;
Nilsen et al., 2014a,b). However, systematic studies to follow
changes in GABA during the entire spectrum of disease progression
where sex and affected and unaffected brain region are taken into
account are missing. The different brain regions such as cortex and
hippocampus have heterogeneous structures and age-related
changes in GABA content may occur at different rates in different
areas with or without Alzheimer’s disease (Davis et al., 1999). For
example, GABAergic signaling dysfunction varies between hippo-
campus and prefrontal cortex during normal aging (McQuail et al.,
2015). For this reason, the knowledge about the changes in the level
of GABA during Alzheimer’s disease progression in different brain
region with age is necessary in order to establish the relevance of
GABAergic dysfunctions in the pathology of Alzheimer’s disease.
Emerging evidence suggests that Alzheimer’s disease dispro-
portionately affects women in both occurrence and severity (Carter
et al., 2012; Musicco, 2009; Viña and Lloret, 2010; van Duijn et al.,
2013). Sex differences in amyloid b (Ab) deposition in transgenic
mice (Callahan et al., 2001; van Duijn et al., 2013) and humans
(Corder et al., 2004) have been reported. The molecular mechanism
accounting for sex-related differences in Alzheimer’s disease re-
mains unknown. In healthy human subjects, sex-specific differ-
ences in GABAergic markers have been reported (Cosgrove et al.,
2007). It has been shown that healthy women have higher
cortical GABA levels thanmen (Cosgrove et al., 2007; Sanacora et al.,
1999). Up to now, no research is present in literature dealing
whether and how sex and age may modulate the GABA levels in
different brain regions during development of Alzheimer’s disease
pathology.
In this article, we present the first systematic longitudinal study
to investigate the brain regionerelated and sex-related differences
in GABA levels during development of disease in Tg2576 mice, a
widely used model of Alzheimer’s disease which mimics patho-
logical aspects of Alzheimer’s disease, including amyloid plaques,
reactive astrocytes in the brain, and impaired spatial learning and
memory (Hsiao et al., 1996; Kobayashi and Chen, 2005; Takeuchi
et al., 2000). Our data demonstrate that age- and sex-related
differences in GABA levels during Alzheimer’s disease exist
among brain regions, such as the hippocampus and the prefrontal
cortex, important for learning, memory, and affection. Our results
also indicate that regional differences in GABA could be at the root
of marked sex disparities observed in incidence, manifestation, and
prognosis of Alzheimer’s disease.
2. Materials and methods
2.1. Animals
In this study, transgenic Tg2576 mice developed and described
earlier (Hsiao et al., 1996) were used as model of Alzheimer’s
disease. The mice contain as transgene the human amyloid pre-
cursor protein (APP695) with the Swedish double mutation(K670N, M671L) under control of a hamster prion protein promoter.
Mice heterozygous for the transgene and wild-type (WT) litter-
mates were on a C57BL/6  SJL background. Mice were housed in
groups of 3e5 animals per cage and separated by sex, with ad
libitum access to water and food at 23 C with 12-hour day/12-hour
night cycles. The cages contained red plastic houses (Techniplast)
and shredded paper flakes to allow nest building. At the age of
4 weeks, transgenicity of the animals was tested by polymerase
chain reaction of tail DNA as described elsewhere (Hsiao et al.,
1996). Mice of both sexes were studied at the ages of 3, 6, 9, 12,
and 18 months. Age-matched nontransgenic littermates served as
controls. For high-resolution magic angle spinning nuclear mag-
netic resonance (HR-MAS NMR) as well as for histological studies, 6
female and 6 male animals were used per age group. All animal
experiments were approved by the institutional animal care and
animal use committee in accordance with the NIH Guide for the
Care and Use of Laboratory Animals.
2.2. Brain preparation
Mice were sacrificed by CO2 inhalation, and brains were quickly
removed. Prefrontal cortex, parietal cortex, hippocampus, and
thalamus were carefully prepared and rapidly frozen by immersing
in liquid nitrogen and subsequently stored at 80 C. For mono-
amine oxidase-B (MaOB), enzymatic assay entire hippocampus was
used. For HR-MAS NMR studies, the individual brain regions were
inserted into a 4 mm zirconium oxide rotor. 10 mL of deuterated
phosphate buffer containing 0.1% (w/v) 3-trimethylsilyl-
2,2,3,3-tetradeuteropropionic acid (TSP) was added as an NMR
reference. The rotor was placed immediately inside the NMR
spectrometer.
For histological studies, mice were sacrificed by CO2 inhalation
and transcardially perfused with phosphate-buffered saline (pH
7.4) followed by 4% buffered paraformaldehyde through the left
cardiac ventricle. After perfusion fixation, the brain was dissected
out and placed in the same fixative for 24 hours at 4 C. After cry-
oprotection in 30% sucrose in 0.1 M phosphate buffer for 3 days, the
brains were snap-frozen in n-hexane at 68 C and stored at 20
C. Coronal sections (30 mm) were cut on a sliding microtome and
collected in 0.1 M phosphate buffer.
2.3. 1H HR-MAS NMR
All 1H HR-MAS NMR experiments were carried out on a Bruker
AVIII 600 MHz NMR spectrometer equipped with a 4 mm HR-MAS
dual inverse 1H/13C probe with a magic angle gradient. Data were
collected with a spinning rate of 6 kHz and a temperature of 277 K.
Bruker TOPSPIN 3.1 software was used to acquire and process the
NMR data.
The 1 dimensional (1D) 1H HR-MAS NMR spectra were recorded
using Carr-Purcell-Meiboom-Gill pulse sequence with water sup-
pression (Maas et al., 1996; Meiboom and Gill, 1958). Each 1D
spectrumwas acquired applying a spectral width of 12 kHz, domain
data points 4k, number of averages 128 with an acquisition time of
170 ms, and a relaxation delay of 2 seconds. Since NMR measure-
ments were done on intact brain tissue, the relaxation delay was set
to a small value to remove short T2 components due to the presence
of lipids. All spectra were processed by an exponential window
function corresponding to a line broadening of 1 Hz and zero-filled
prior to Fourier transformation. 1H HR-MAS NMR spectra were
phased and baseline corrected using TOPSPIN 3.1. The measure-
ment time (including optimization of NMR parameters and data
acquisition) of 1H HR-MAS NMR spectroscopy for each sample was
approximately 6 minutes. Two dimensional (2D) homonuclear
correlation spectroscopy (1H-1H COSY) and J-resolved
U. Roy et al. / Neurobiology of Aging 62 (2018) 168e179170measurements in magnitude mode were performed using Bruker’s
standard pulse program library. For parameters used for COSY and
J-resolved measurements, see Supplementary Material.
2.4. MaOB enzymatic activity assay
Enzymatic activity of MaOB was measured as described previ-
ously (Jo et al., 2014). Frozen hippocampus tissues from eachmouse
were homogenized, and large debris was removed by weak
centrifugation. Subsequently, the supernatant was collected, and
mitochondria-rich fraction was obtained by centrifuging the
supernatant at 13,000 rpm for 20 minutes. The pellet was resus-
pended in phosphate buffer, and 30 mg were used in each well to
determine the activity of the MaOB using an Amplex Red Mono-
amine oxidase Assay Kit (Molecular Probes) according to the
manufacturer’s instructions. After enzyme reaction, hydrogen
peroxide, which is produced by MaOB activity, is measured by a
color change of Amplex red reagent. The color change was quan-
tified by measuring absorbance at 590 nm with Infinite M200 PRO
microplate reader (TECAN).
2.5. Histology
To detect Ab deposition, brain sections (30 mm thickness) were
subjected to immunohistochemistry using the monoclonal Ab
antibody 4G8 (1:2000). Immunolabeling was visualized by using
the ABC kit (Vectastain) according to the manufacturer’s in-
structions. Images of the histological sections were obtained using a
Leica DM RE HC microscope interfaced to a Leica DC500 3CCD
digital camera.
For fluorescent labeling of Ab deposition using Thioflavin-S
(ThS), sections (30 mm thickness) were incubated with 1% ThS
(Sigma) for 20 minutes, followed by 40 minutes incubation in 80%
ethanol and a final rinse in distilled water, dehydrated in toluene,
and covered with coverslip using Entellan. For fluorescent immu-
nolabeling, the primary antibodies used were as follows: mouse
anti-GFAP (glial fibrillary acidic protein) for labeling of astrocytes
(1:1000); rabbit anti-GAD (glutamic acid decarboxylase) antibody
for GABAergic neurons (1:4000); rabbit anti-IBA-1 for labeling
microglia (1:500); rabbit anti-MaOB (1:100); and mouse anti-
putrescine (1:50). The mouse brain slices (30 mm thickness) were
pretreated with 60% methanol (30 minutes), followed by washes in
0.1 M tris buffered saline and blocked in tris buffered saline con-
taining 0.3% Triton X-100 and 5% goat serum for 30 minutes. Sub-
sequently slices were incubated overnight with primary antibodies.
After washing in PBS 3 times, sections were incubated with corre-
sponding fluorescence secondary antibodies (Dianova 1:400) for
1 hour. Confocal laser scanning microscopy (LSM 510, Zeiss, Ger-
many) was performed to reveal colocalization of GFAP/GAD/ThS
staining or GFAP/MaOB/ThS or IBA-1/putrescine/ThS. ThS (green
fluorescence) was visualized by excitation at 488 nm and detection
of emission at 510 nm using a low-range band pass (505e530 nm).
The Cy3-labeled antigens were visualized using excitation at
543 nm and emission at 570 nm and the Cy5 using excitation at
650 nm and emission at 670 nm. Specificity of primary antibody
and immunoreaction was confirmed by omitting primary anti-
bodies or changing probes of the secondary antibodies.
2.6. Data processing
2.6.1. Quantification of metabolites
All of the spectra were referenced, baseline-, phase-corrected
and analyzed by using MestReNova v.8.0 (Mestrelab Research
S.L.). Quantification of metabolites was performed by integrating
the distinct characteristic signal of GABA with respect to theintensity of total creatine (tCr) resonance using MestReNova
(MNOVA). To ensure that only desired region of GABA and tCr peak
from all the spectra is taken into account, line fitting option in the
MNOVAwere used. Metabolite concentrations (mmol/g tissue) were
calculated with the formula Cx ¼ (Ax/ATSP)  (9/nx)  (CTSP/M) with
Ax and ATSP being the areas under the signals of metabolite x and
TSP, 9 and nx the number of protons of TSP andmetabolite x evoking
the signals, CTSP is the concentration of TSP in the sample analyzed
(in nmol), and M is the fresh weight (mg) of the brain tissue
measured. The method was adapted from the previous publications
(Lalande et al., 2014; Robert et al., 2011).
2.6.2. Image analysis of brain sections
For quantitative histological analysis, the cortex and hippo-
campus region was outlined according to the “Allen Brain Atlas”
with the brain explorer program (http://mouse.brainmap.org) as
the reference atlas. The images were exported and further analyzed
in ImageJ software (ImageJ, USA). The colors were unmixed by
converting the image into 16-bit binary image and then appropriate
threshold was applied. After that the stained area was selected and
the percentage of the total area was calculated using analyze par-
ticles. Any alterations in brightness and contrast were equally
applied to the entire image set. The quantification of Ab plaque load,
astrocytes, and GAD was performed, and data were exported to
Origin Pro v. 8 software for data analysis. For image coregistration,
immunohistological images were matched with each other using
common anatomical landmarks such as the ventricles, corpus
callosum, and hippocampal fissure.
2.6.3. Statistical analyses
All statistical analyses (t-test and analysis of variance) of the
NMR and histological quantifications were performed with Origin
Pro v.8. The paired and/or unpaired Student’s t-test was used to
compare mean values. F-values were calculated and F-values larger
than 2.8 (p < 0.05) were considered significant. Kolmogorov-
Smirnov normality tests were performed which confirmed that
the longitudinal HR-MAS NMR data were normally distributed for a
particular age/genotypewith a probability ranging from0.5 to 0.9. A
KruskaleWallis 1-way analysis of variance along with rank test was
implemented on the NMR data to compare the median of metab-
olites levels for all group comparisons. This method confirms that
samples come from the same population for a particular age, sex,
and genotype. Tests for homogeneity of variances between different
ages (3, 6, 9,12, and 18months) were computedwith Origin Pro v. 8.
No statistically significant change in variance was observed in
particular age for any genotype. Subsequent ManneWhitney tests
were used to make pairwise comparisons between different mice
groups. Bonferroni correction for multiple comparisons (20
comparison ¼ 4 regions  5 time point) was applied to identify
significance of differences among different age groups.
3. Results
Alterations in GABA concentrations are associated with several
neurological disorders, including AD. Interestingly, previous studies
with healthy subjects have shown that women have higher cortical
GABA levels than men (Cosgrove et al., 2007). Here, we wanted to
address the following research questions: Is the sex-specific
difference in GABA uniformly distributed over the brain or more
localized to specific regions? How do the levels of GABA change
during normal aging? How are sex-specific differences in GABA
influenced during AD progression? To find answers to these ques-
tions, we applied HR-MAS NMR methods to measure the concen-
trations of GABA in prefrontal cortex, parietal cortex, hippocampus,
and thalamus regions of male and female Tg2576 mice at the age of
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astrocytes in GABAergic dysfunction and sex discrimination in AD.
3.1. Detection of GABA in intact brain tissues
The development of noninvasive and accurate methods for the
measurement of GABA in intact tissues as well as under in vivo
conditions using 1H NMR has been an active area of research in the
recent years (Ke et al., 2004; O’Gorman et al., 2011). GABA has a
complex resonance peak pattern, which extensively overlaps with
other more intense resonance peaks. Therefore, noninvasive mea-
surement of GABA in intact tissue using 1D 1H NMR has been a great
challenge (Braakman et al., 2008; Firat et al., 2011). In this work, we
applied HR-MAS NMR in 1 and 2 dimension (2D COSY and
J-resolved 2D 1H HR-MAS NMR) to accurately resolve the peaks of
GABA in intact brain tissues without any extraction, thus measuring
GABA in its native environment. Fig. 1 obtained from parietal cortex
of WT mice shows that 2-dimensional COSY and 1H J-resolved
(JRES) NMR disperses the overlapping resonances into a second
dimension, reducing congestion and increasing metaboliteFig. 1. Detection of the inhibitory neurotransmitter GABA in intact brain tissue by HR-MAS N
COSY spectra showing expension of the GABA region; (C) J-resolved proton 2D HR-MAS NMR
of tCr and GABA resonance peaks. The resonance line from TSP was used as a reference of
HR-MAS NMR, high-resolution magic angle spinning nuclear magnetic resonance; MRS, maspecificity. Using HR-MAS NMR method, the concentrations of
multiple metabolites were simultaneously determined. Although
several brain metabolites have been assigned and quantified (see
Supplementary Figs. 1 and 2 and Supplementary Tables 1 and 2),
here, we focus on the use of this technique to quantify age- and sex-
specific differences in GABA in various brain regions of WT and
Tg2576 mice. Four different brain regions were chosen: prefrontal
cortex, parietal cortex, hippocampus, and thalamus which repre-
sent brain areas characterized by different neuronal cell types,
metabolism, and cytoarchitecture and are differently affected by
Alzheimer’s disease pathology such as deposition of Ab. In addition,
to understand the mechanism of sex-specific fluctuations in GABA
levels, we also analyzed simultaneously the concentration of
excitatory neurotransmitter, glutamate, and cell typeespecific
markers such as N-acetyl aspartate (NAA) and m-Ins.
3.2. Age- and sex-dependent changes in GABA levels in WT mice
In order to evaluate prospective of age- and sex-related differ-
ences in GABA in normal aging, we analyzed GABA levels inMR spectroscopy. (A) A representative proton spectra from parietal cortex; (B) 2D 1H-1H
; (D) stack plot of J-resolved 2D MRS shown in (C) better illustrates the intensity changes
chemical shift frequency at 0.0 ppm. Abbreviations: GABA, gamma-aminobutyric acid;
gnetic resonance spectroscopy; TSP, 3-trimethylsilyl-2,2,3,3-tetradeuteropropionic acid.
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18 months.
As illustrated in Fig. 2, in general, in both male and female mice,
the level of GABA increased with age in parietal as well as
prefrontal cortex from 3 to 9 months of age and then showed a
decreasing trend at 12 months of age. Interestingly, female mice
consistently showed high levels of GABA in both parietal cortex
and prefrontal cortex regions as compared to male mice between 6
and 12 months of age. The high levels of GABA in females as
compared to males persisted also at older ages in prefrontal cortex
(Fig. 2B). However, in parietal cortex, no significant difference was
observed at the age of 18 months (Fig. 2A). The highest sex-specific
difference in cortical GABA was seen at the age of 9 months in
parietal cortex (Fig. 2A) and at the age of 18 months in prefrontal
cortex (Fig. 2B). Taken together, our results show that female mice
have significantly higher cortical GABA level as compared to male
mice. These results are consistent with previous magnetic reso-
nance spectroscopic studies in humans, which showed that
cortical GABA levels in females are higher as compared to healthy
male subjects (Sanacora et al., 1999). However, altered sex-specific
GABA levels in specific cortical regions with age have not been
reported before. Our results show that high levels of cortical GABAFig. 2. Longitudinal monitoring of region- and sex-related differences in GABA levels in heal
cortex, and hippocampus of female (black circle) and male (open circle) wild-type mice w
GABA/Glu ratio in parietal cortex and hippocampus of 12- and 18-month-old male and fem
mice at old age as compared to male mice; however, in prefrontal cortex, the ratio of GABA/
mean (n ¼ 9). (##p < 0.0001, #p < 0.001, **p < 0.01, *p < 0.05). Abbreviations: GABA, gammexist in female mice as compared to male mice above 6 months of
age in both parietal and prefrontal cortex, although in parietal
cortex the sex-specific difference disappears at 18 months of age.
In prefrontal cortex, the level of GABA remained significantly
higher in female than male at 18 months of age.
In hippocampus, the level of GABA shows a consistent increase
with age (until 12 months) in both male and female mice and
subsequently the level of GABA declines at older age (Fig. 2C).
A decline in hippocampal GABA during aging has been previously
suggested to be linked to low expression of GAD, an enzyme
involved in synthesizing GABA from glutamate (McQuail et al.,
2015; Stanley and Shetty, 2004). No sex-specific differences in
GABA levels were observed in hippocampus until 9 months of age.
However, a significant sex-specific difference in GABAwas observed
at the age of 12 months, where females have higher GABA as
compared to age-matched male mice. Conversely, the sex-specific
difference in hippocampal GABA level has been reversed in older
mice (18 months), where females have lower GABA levels as
compared to aged-matched male mice (Fig. 2C). Interestingly, the
GABA/Glu ratio in hippocampus was also lower in female mice
(between 12 and 18 months), while, in male mice, such ratio was
kept consistent (Fig. 2D).thy control mice. Age-dependent differences in GABA level in parietal cortex, prefrontal
ith age. (A) Parietal cortex; (B) prefrontal cortex; (C) hippocampus; (D) comparison of
ale Tg2576 mice, showing steeper decline of GABA/Glu ratio in hippocampus of female
Glu remained significantly higher in female than male mice. Values are average  SE of
a-aminobutyric acid; Glu, glutamate; SE, standard error.
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progression
To investigate the apparent GABAergic vulnerability of different
brain regions to Alzheimer’s disease and to examine the influence
of sex on GABA modulation, we performed a longitudinal study to
compare GABA levels in parietal cortex, prefrontal cortex, hippo-
campus, and thalamus regions of transgenic Tg2576 mice and their
nontransgenic littermates (WT). Fig. 3 shows systematic longitu-
dinal monitoring of GABA levels relative to tCr in 4 brain regions of
male and female transgenic and WT mice at different ages
(3e18 months). The absolute concentration of GABA changes andFig. 3. Longitudinal monitoring of region- and sex-related differences in GABA levels dur
parietal cortex, (B) prefrontal cortex, (C) hippocampus, and (D) thalamus region of wild-typ
female mice together. Middle column (_) shows data of male mice (open circle), and right c
(n ¼ 9) (**p < 0.01, *p < 0.05). Abbreviations: GABA, gamma-aminobutyric acid; SE, standar
referred to the Web version of this article.)statistics of all group comparisons are reported in Supplementary
Tables 3 and 4. In the thalamus, no significant differences in
GABA levels were observed in transgenic mice as compared to WT
mice at all the ages (3e18 months) (Fig. 3D).
Fig. 3 shows longitudinal monitoring of GABA levels in the
parietal cortex (Fig. 3A) and the prefrontal cortex (Fig. 3B) of male
and female Tg2576mice and their nontransgenic littermates. When
data of male and female mice were taken together, the level of
GABA was marginally lower in transgenic mice as compared to
control mice in both parietal cortex as well as in prefrontal cortex.
However, the difference between WT and transgenic mice was not
statistically significant. Conversely, when the data of male anding Alzheimer’s disease progression. Age-dependent differences in GABA level in (A)
e (black) and Tg2576 mice (red). Left column (\ þ _) shows combined data of male and
olumn (\) shows data from female mice (closed circle). Value are average  SE of mean
d error. (For interpretation of the references to color in this figure legend, the reader is
U. Roy et al. / Neurobiology of Aging 62 (2018) 168e179174female mice were separately evaluated, significantly lower levels of
GABAwere observed in both parietal cortex (Fig. 3A) and prefrontal
cortex (Fig. 3B) of transgenic mice as compared to age-matched
control mice.
The influence of sex on GABA decline during aging of Tg2576
mice was not apparent in the parietal cortex (Fig. 3A). In prefrontal
cortex, male Tg2576 mice display very similar levels at 3 and
18 months of age, whereas male WTmice display an increase GABA
level between 3 and 18 months. For female mice, both Tg2576 and
WT mice display an increase in their prefrontal GABA levels
between 3 and 18 months; however, the increase for WT female
mice was greater than the 1 for Tg2576 mice (Fig. 3B). Histological
analysis of Ab plaque load in both parietal and prefrontal cortex
region has been performed using ThS staining as well as by using
polyclonal anti-Ab 40e42. As shown in Fig. 4, substantially higher
plaque load was observed in parietal cortex of female as compared
to male mice. However, in prefrontal cortex, no significant
sex-specific difference in plaque load was observed. In parallel, we
also analyzed the levels of reactive astrocytes by observing the
GFAP immunoreactivity (Supplementary Fig. 3). An increase in the
GFAP immunoreactivity was observed in both parietal and pre-
frontal cortex of Tg2576 brain as compared to age-matched control
mice. In parietal cortex, the GFAP-positive astrocytes were signifi-
cantly higher in female mice as compared to male mice especiallyFig. 4. Histological analysis of sex-specific differences in Ab plaques load and GAD staining in
images (AeD) and quantification (E and F) of thioflavin-S-stained Ab plaques (ThS) and GAD
female (\) wild-type (WT) and Tg2576 (TG) mice. Scale bar: 250 mm in A and B and 50
decarboxylase.around amyloid plaques (Supplementary Fig. 3C and D). Compre-
hensive statistical data of histology for all group comparison is
presented in the Supplementary Table 5.
GABA is synthesized in neurons by glutamic acid decarboxylase
(GAD), an enzyme involved in synthesizing GABA from glutamate
(see Supplementary Fig. 4). Using antibodies against GAD, we
analyzed the expression level of GAD in parietal and prefrontal
cortex. Significantly lower levels of GAD were observed in both
cortex regions of Tg2576 mice as compared to age-matched WT
mice (Fig. 4CeF). These results indicate that low GABA observed in
parietal and prefrontal cortex of transgenic mice may be due to its
low production via GAD route. The decline in GADwas substantially
higher in female as compared to male Tg2576 mice in parietal
cortex, which is inversely correlated with high plaque load in
parietal cortex of female as compared to male mice (Fig. 4 E and F).
3.4. Hippocampal GABA shows dynamic changes during disease
progression in Tg2576 mice
The influence of sex on hippocampal GABA level during
Alzheimer’s disease is shown in Fig. 3C. In young adult mice (3 and
6 months old), the hippocampal GABA level was not different in
transgenic and control mice of both sex. Remarkably, at 9 months of
age hippocampal GABA level was significantly lower inmale Tg2576parietal and prefrontal cortex regions of Tg2576 and WT mice. Representative confocal
staining in parietal (A, C, E) and prefrontal (B, D, F) cortex of 18-month-old male (_) and
mm in C and D. #p < 0.05, **p < 0.05, *p < 0.05. Abbreviation: GAD, glutamic acid
U. Roy et al. / Neurobiology of Aging 62 (2018) 168e179 175mice as compared to male WT mice (Fig. 3C). On the other hand, at
12 months of age the level of GABA was although lower in both
male and female Tg2576 mice when compared to their respective
control mice, the difference in GABA levels betweenWTand Tg2576
mice was more pronounced in female than male mice (Fig. 3C).
Remarkably, at older age (18 months), the hippocampal GABA level
was significantly higher in female Tg2576 mice as compared to
age-matched control mice (Fig. 3C). A slightly higher hippocampal
GABA level was also seen in 18-month-old male Tg2576 mice as
compared to age-matched control mice (Fig. 3C). We also examined
the levels of reactive astrocytes as well as Ab plaque deposition in
hippocampus region of 18-month-old transgenic and WT mice of
both sex (Fig. 5A; Supplementary Figs. 5 and 6). ThS staining
showed significantly higher plaque load in female than male mice.
As shown in Fig. 5A, numerous reactive astrocytes (GFAP staining)
were clustered around the amyloid plaques. Interestingly, the
plaque load was especially higher in the stratum lacunosum
moleculare and in the dentate gyrus of hippocampus in female
transgenic as compared to male transgenic mouse brain.
Next, we examined the expression levels of GAD, which is
essential for the production of GABA in GABAergic neurons (Martin
and Rimvall, 1993). Interestingly, we found that GAD is minimally
expressed in hippocampus of Tg2576 mice especially in the areas
surrounding the reactive astrocytes (Fig. 5A; Supplementary Fig. 5).
In addition, glutamate, a substrate for GAD was also significantly
lower in hippocampus of transgenic mice as compared to
age-matched control mice (Fig. 5C). Furthermore, the level of
glutamine (Gln) was found to be lower in hippocampus of Tg2576
mice (Fig. 5C), reflecting a decreased activity of Glu-Gln cycle that
operates between astrocytes and neurons (Hertz, 2013; Massucci
et al., 2013). The number of activated astrocytes in hippocampus
was significantly higher in female transgenic than age-matched
male transgenic mice. The cellular microstructural changes in hip-
pocampus of male and female Tg2576 mice were also confirmedFig. 5. Increased hippocampus GABA in female Tg2576 mice may be linked to its production
astrocytes in hippocampus of 18-month-old male (_) and female (\) WT and Tg2576 (TG) mic
through hippocampus of male and female TG mice (scale bar, 50 mm). Bottom, quantitative a
namely NAA (marker of neuron) and m-Ins (marker of astrocytes) and their ratios in hippoca
region showing changes in NAA and m-Ins; (bottom) concentration of NAA and m-Ins and t
WT and TG mice. Value are average  SE of mean (n ¼ 9). ##p < 0.0001, #p < 0.001, **p <
decarboxylase; GFAP, glial fibrillary acidic protein; Gln, glutamine; Glu, glutamate; HR-MAS
aspartate; SE, standard error.based on analysis of 2 cell typeespecific metabolic signatures,
namely: NAA and m-Ins. These particular MR-responsive metabo-
lites are specifically compartmentalized within neurons and as-
trocytes, respectively (Brand et al., 1993). NAA is found almost
exclusively in neurons, both in the cell body as well as in neurites
and axons (Simmons et al., 1991) and myo-inositol (m-Ins) is pre-
dominantlydthough likely not exclusivelydfound in the astrocytic
cell body and branches (Brand et al., 1993). Thus, each metabolite
can in principle report on a specific cell population’s environment.
As shown in Fig. 5B, a dramatic increase in the concentration of
m-Ins was observed in Tg2576 mice, which was not seen in WT
mice. The increase in m-Ins is substantially higher in female than
male Tg2576 mice. In contrast to m-Ins, a reduction in the levels of
NAA, was found in transgenic mice than WT mice, and this decline
in NAAwasmore substantial in female thanmale mice (Fig. 5B) (see
Supplementary Table 6 for statistical group comparison). These
results suggest significant loss of neuronal integrity and viability as
indicated by reduction in NAA and a dramatic increase in the
number of reactive astrocytes as reflected by increase in m-Ins at
older age in Tg2576 mice and predominantly in female transgenic
mice.
3.5. Increased hippocampal GABA in Tg2576 mice is produced via
MaOB route
Besides the GAD route, GABA can also be produced by the
degradation of putrescine via MaOB route, as previously reported in
the brain and in cultured astrocytes (Jo et al., 2014; Laschet et al.,
1992; Yarishkin et al., 2015). MaOB is expressed predominantly in
astrocytes and its activity has been shown to be increased in human
Alzheimer’s disease brain (Saura et al., 1994; Nakamura et al., 1990)
as well as in APP/PS1 mice (Jo et al., 2014). MaOB activity was
determined inmitochondrial-rich fraction fromhippocampus of 12-
and 18-month-old male and femaleWTand Tg2576mice. As shownin activated astrocytes. (A) Immunostaining and quantification of Ab, GAD, and activated
e. Top, representative confocal images of thioflavin-S-, GAD-, and GFAP-stained sections
nalysis of Ab load, GFAP, and GAD stained area. (B) Probing cellular-specific metabolites
mpus of 18-month-old male and female WT and TG mice. (Top) HR-MAS NMR spectral
heir ratios. (C) Levels of Glu and Gln in hippocampus of 18-month-old male and female
0.01, *p < 0.05. Abbreviations: GABA, gamma-aminobutyric acid; GAD, glutamic acid
NMR, high-resolution magic angle spinning nuclear magnetic resonance; NAA, N-acetyl
U. Roy et al. / Neurobiology of Aging 62 (2018) 168e179176in Fig. 6A, MaOB activity was significantly elevated in 18-month-old
Tg2576 mice, whereas 12-month-old mice did not show any sig-
nificant difference in the activity of MaOB as compared to age-
matched control mice. These results are in line with the observed
increase in hippocampal GABA levels as well as an increased in the
number of activated astrocytes surrounding the amyloid plaques
which were detected at the age of 18 months and not at 12 months
of age. Furthermore, comparison of MaOB activity in male and fe-
male Tg2576 mice showed significantly elevated activity in female
mice as compared to male mice (Fig. 6A; Supplementary Table 7).
Fig. 6B shows the colocalization of MaOB in GFAP-positive reactive
astrocytes. In addition, we found increased immunoreactivity of
putrescine in Tg2576 mice, especially around amyloid plaques
(Supplementary Fig. 7). These results clearly indicate that aberrant
upregulation ofMaOB in activated astrocytesmay be responsible for
high levels of hippocampal GABA seen in old Tg2576mice andmore
prominently in female Tg2576 mice.
4. Discussion
Age and sex are risk factors of Alzheimer’s disease. GABA is a
major inhibitory neurotransmitter, involved in essentially all brain
circuits (Lehmann et al., 2012; Li et al., 2016). However, the relevance
of GABAergic dysfunction in sex discrimination during Alzheimer’s
disease progression remains unknown. In the present study, we
applied HR-MAS NMR and demonstrate that GABA levels undergo
dynamic alterations during disease progression in Tg2576mice, and
its level significantly depends on age, sex, and brain regions.
At first, we have analyzed sex-specific differences in GABA in
various brain regions during normal aging (Fig. 2). High levels of
cortical GABAwere observed at and above 6months of age in female
mice as compared to male. However, at older age the sex-specific
difference in GABA vanishes in parietal cortex but becomes larger
inprefrontal cortex. In hippocampus, a steeper decline inGABA level
was observed in female than male mice between 12 and 18 months
of age. Interestingly, the GABA/Glu ratio in hippocampus was also
found to be lower in female mice (between 12 and 18 months),
while, in male mice, such ratio was kept consistent. These results
indicate that disruption of the inhibitory/excitatory balance at old
age is prevalent in female brain. In aged females, high GABA in
prefrontal cortex, and low in hippocampus as compared to male
mice suggests that sex may have an influence on age-related shifts
in inhibition of different forms of memory function, that is,
hippocampus-dependent spatial reference memory in female and
prefrontal cortexedependent working memory in male mice.
We next followed the influence of sex on altered GABA level
during disease progression in the Tg2576 mice (Fig. 3). SignificantlyFig. 6. Increased hippocampal GABA in Tg2576 mice is produced via MaOB route. (A) (left
activity normalized to the activity of WT mice in the whole hippocampus in 12- and 18-mon
and MaOB showing high expression of MaOB in activated astrocytes in hippocampus of 18-m
acid; GFAP, glial fibrillary acidic protein.lower levels of GABA were observed in both parietal cortex and
prefrontal cortex of transgenic mice as compared to age-matched
control mice. Remarkably the decline in GABA in both cortex
regions of Tg2576 mice was observed as early as 6 months of age,
long before the accumulation of insoluble Ab into amyloid plaques
occurs. The decline in GABA in parietal and prefrontal cortex of
young transgenic mice could be attributed to the susceptibility of
GABAergic neurons to neurotoxic properties of soluble Ab oligomer
which occur relatively early when compared to other neuronal
types in Alzheimer’s disease (Krantic et al., 2012; Ono and Yamada,
2011; Ramos et al., 2006). Using the TgCRND8mousemodel, Krantic
et al. have argued that Ab toxicity leads to GABAergic neuron
dysfunction before their losses at a later stage (Krantic et al., 2012).
In postmortem human studies, a quantitative loss of neurons in the
cerebral cortex as well as GABA has been reported (Seidl et al.,
2001). The influence of sex on the GABA decline during aging of
Tg2576 mice was not apparent in parietal cortex region (Fig. 3A).
However, prefrontal cortex GABA levels were more significantly
reduced in old male Tg2576 mice (18 months old) as compared to
age-matched female Tg2576 mice (Fig. 3B). In old Tg2576 mice, a
low level of GAD was observed in both cortex regions as compared
to control mice (Fig. 4), indicating that low GABA observed in
parietal and prefrontal cortex of transgenic mice may be due to its
low production via GAD route.
Interestingly, in hippocampus, the time course of GABA levels
shows dynamic changes and exhibits significant sex-specific dif-
ferences as disease progressed (Fig. 3C). At young age (9 months),
hippocampal GABA level declined in male but not in female Tg2576
mice. These results indicate that young females may be protected at
preplaque stage against aspects of Ab oligomer toxicity and mito-
chondrial dysfunction due to the protective effects of estrogen, as
has been proposed in earlier studies (Lloret et al., 2008; Nilsen et al.,
2006). Interestingly, at 12 months of age, the decline in GABA,
although observed in both male and female mice, was more pro-
nounced in female mice than male mice. The onset of reproductive
senescence in female Tg2576 mice starts around 12 months of age
which also coincides with the start of senile plaques formation as
well as the decline in circulating estrogen (Callahan et al., 2001;
Zheng et al., 2002). Previous in vivo studies in Tg2576 mice have
shown that estrogen depletion leads to the accumulation of Ab in
the CNS, which can be reversed through replacement of estradiol
(Zheng et al., 2002). Taken together, our results of a significant
decrease in GABA in females at 12 months of age as compared to
control mice indicate that low levels of estrogenmay be responsible
for significant decline in GABAergic neurotransmission.
Remarkably at older age, hippocampal GABA increased signifi-
cantly in Tg2576 mice as compared to age-matched control mice,) reaction diagram of the MaOB enzyme activity assay in hippocampus; (right) MaOB
th-old male and female WT and TG mice (n ¼ 8, *p < 0.05). (B) Immunostaining of GFAP
onth-old female WT and Tg2576 (TG) mice. Abbreviations: GABA, gamma-aminobutyric
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Furthermore, we found significantly high number of Ab plaque in
female thanmale Tg2576mice, especially in the stratum lacunosum
moleculare and in the dentate gyrus of hippocampus. The dentate
gyrus is known as the principal gateway of cortical input to the
hippocampus and is critical for the formation and recall of memory
(Kesner, 2007; Nakashiba et al., 2012), and the stratum lacunosum
moleculare hosts a strong feed-forward inhibitory network
composed of various types of GABAergic interneurons (Freund and
Buzsáki, 1996). Thus, amyloid pathology in these regions can have
significant impact on memory impairment. To analyze whether
increased level of GABA in the hippocampus of old Tg2576 mice is
due to its elevated production, we examined the expression levels
of GAD, which is essential for the production of GABA in GABAergic
neurons (Martin and Rimvall, 1993). Interestingly, we found that
GAD expression was very low in hippocampus of Tg2576 mice
especially in the areas surrounding the Ab plaque (Fig. 5A). These
results indicate that high hippocampal GABA seen in old transgenic
mice may not be due to high glutamate to GABA conversion cata-
lyzed by GAD.
Recent studies in another Alzheimer’s disease mouse model
(APP/PS1) show an increase in hippocampal GABA levels which
was demonstrated to be due to increased production of GABAFig. 7. A model diagram of GABAergic signaling in the pathogenesis of Alzheimer’s disease
regions of Tg2576 mice. In cortex (at all the ages) and hippocampus (at the age of 12 mont
broken pathway). Decrease in GAD activity as well as decrease in Glu and Gln signifies this n
neurons induced by Ab oligomer toxicity and mitochondrial dysfunction (Tu et al., 2014). In
reactive and produce high amount of GABA from putrescine by MaOB route (blue solid pathw
GABA receptors which in turn strongly inhibit synaptic release, leading to impairment of
astrocytes and high amount of hippocampal GABA in female signifies that synaptic dysfu
Abbreviations: aKG, a-ketoglutarate; Best1, Bestrophin 1 channel; GABA, gamma-aminobut
specific GABA transporter; Gln, glutamine; Glu, glutamate; GS, glutamine synthetase; LTP,
(peptide neurotransmitter); NMDAR, N-methyl-D-aspartate receptor (Glu receptor); PAG, p
figure legend, the reader is referred to the Web version of this article.)from putrescine in reactive astrocytes (Jo et al., 2014). It has been
proposed that an abnormal increase in tonic GABA release from
reactive astrocytes in the hippocampus may be directly respon-
sible for the memory impairment in Alzheimer’s disease. In this
study, we observed that Tg2576 mice have also significantly high
number of activated astrocytes in hippocampus, and this number
is higher in female than male Tg2576 mice. Therefore, we
hypothesized that in female Tg2576 mice high GABA levels in
hippocampus may be linked to high GABA production in astro-
cytes. To assess this possibility, we examined the activity of
MaOB, a key enzyme involved in the conversion of putrescine to
GABA, and is predominantly expressed in astrocytes (Nakamura
et al., 1990; Saura et al., 1994). The MaOB activity was signifi-
cantly elevated in old Tg2576 mice and more elevated in female
than male Tg2576 mice (Fig. 6A). The expression of MaOB was
clearly elevated in activated astrocytes in hippocampus (Fig. 6B).
These results suggest that the upregulation of MaOB in activated
astrocytes may be responsible for high level of GABA seen in
hippocampus of old Tg2576 mice and more significantly in female
Tg2576 mice. Taken together, these results indicate that an
abnormal increase in tonic GABA release from reactive astrocytes
in the hippocampus may be responsible for memory impairment
in old Tg2576 mice.based on observed divergent changes in GABA that occur in hippocampus and cortex
hs), low levels of GABA may be attributed to its reduced synthesis via GAD route (red
otion. The reductions in GABA may reflect loss or dysfunction of a subset of GABAergic
hippocampus of older mice (18 months), diseased astrocytes around plaques become
ay). Consequently, GABA from putrescine released via Best1 channel activates neuronal
synaptic plasticity and memory function (Jo et al., 2014). Higher number of activated
nction and memory impairment is more pronounced in female than male TG mice.
yric acid; GABAA GABAB, GABA receptors; GAD, glutamic acid decarboxylase; GAT3/4,
long-term potentiation; NAA, N-acetyl aspartate; NAAG, N-acetylaspartylglutamic acid
hosphate activated glutaminase. (For interpretation of the references to color in this
U. Roy et al. / Neurobiology of Aging 62 (2018) 168e179178A model diagram of GABAergic signaling in the pathogenesis of
Alzheimer’s disease based on our observation of divergent changes
in GABA that occur in hippocampus and cortex regions of Tg2576
mice is shown in Fig. 7. In cortex (at all the ages) and hippocampus
(at the age of 12 months), low levels of GABA may be attributed to
its reduced synthesis via GAD route. A decrease in GAD activity as
well as decreases in Glu and Gln signifies this notion. The
reductions in GABA may reflect loss or dysfunction of a subset of
GABAergic neurons induced by Ab oligomer toxicity and mito-
chondrial dysfunction (Moreira et al., 2010; Reddy and Beal, 2008;
Tu et al., 2014). In the hippocampus of older mice (18 months),
astrocytes around plaques become reactive and produce high
amount of GABA from putrescine by MaOB route. Consequently,
GABA released via the Best1 channel activates neuronal GABA
receptors, which in turn strongly inhibit synaptic release, leading to
impairment of synaptic plasticity and memory function as also has
been confirmed in another mouse model (APP/PS1) (Jo et al., 2014).
The higher number of activated astrocytes and high amounts of
hippocampal GABA in females signify that synaptic dysfunction and
memory impairment are more pronounced in females that can be
at the root of marked sex disparities observed in Alzheimer’s
disease incidence.
Taken together, our results demonstrate that GABA levels
undergo dynamic alterations during diseased progression in Tg2576
mice, and its level significantly depends on age, sex, and brain
regions. The influence of sex on GABA levels that occur during
Alzheimer’s disease in aged hippocampus and prefrontal cortex
offer unique challenges from the perspective of treating memory
decline. Based on the mechanistic data described previously, ther-
apeutics that target inhibitory changes in 1 brain region might be
expected to exacerbate age-related dysregulation of GABAergic
signaling in another. Thus, different therapeutic strategies may be
required for improving memory functions supported by the
hippocampus and prefrontal cortex.
Disclosure statement
The authors report no disclosures or conflicts of interest relevant
to the current work.
Acknowledgements
This work was supported by grants from Alzheimer Forschung
Initiative e.V. (AFI, Grant Nr 13810). The authors are grateful to Dr
Karen Hsiao Ashe (University of Minnesota, USA) for providing the
initial three Tg2576 F1 mice for further breeding. They thank Dr
Holger Scheidt for technical help during HR-MAS NMR
measurements.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.neurobiolaging.2017.
10.015.
References
Bareggi, S.R., Franceschi, M., Bonini, L., Zecca, L., Smirne, S., 1982. Decreased csf
concentrations of homovanillic acid and g-aminobutyric acid in Alzheimer’s
disease: age- or disease-related modifications? Arch. Neurol. 39, 709e712.
Braakman, N., Oerther, T., de Groot, H.J.M., Alia, A., 2008. High resolution localized
two-dimensional MR spectroscopy in mouse brain in vivo. Magn. Reson. Med.
60, 449e456.
Brand, A., Richter-Landsberg, C., Leibfritz, D., 1993. Multinuclear NMR studies on the
energy metabolism of glial and neuronal cells. Dev. Neurosci. 15, 289e298.Callahan, M.J., Lipinski, W.J., Bian, F., Durham, R.A., Pack, A., Walker, L.C., 2001.
Augmented senile plaque load in aged female b-amyloid precursor protein-
transgenic mice. Am. J. Pathol. 158, 1173e1177.
Canter, R.G., Penney, J., Tsai, L.H., 2016. The road to restoring neural circuits for the
treatment of Alzheimer’s disease. Nature 539, 187e196.
Carter, C.L., Resnick, E.M., Mallampalli, M., Kalbarczyk, A., 2012. Sex and gender
differences in Alzheimer’s disease: recommendations for future research.
J. Womens Health (Larchmt) 21, 1018e1023.
Corder, E.H., Ghebremedhin, E., Taylor, M.G., Thal, D.R., Ohm, T.G., Braak, H., 2004.
The biphasic relationship between regional brain senile plaque and neurofi-
brillary tangle distributions: modification by age, sex, and APOE polymorphism.
Ann. N.Y. Acad. Sci. 1019, 24e28.
Cosgrove, K.P., Mazure, C.M., Staley, J.K., 2007. Evolving knowledge of sex differences
in brain structure, function and chemistry. Biol. Psychiatry 62, 847e855.
Davis, A.M., Ward, S.C., Selmanoff, M., Herbison, A.E., McCarthy, M.M., 1999.
Developmental sex differences in amino acid neurotransmitter levels in hypo-
thalamic and limbic areas of rat brain. Neuroscience 90, 1471e1482.
Dulla, C.G., Coulter, D.A., Ziburkus, J., 2016. From molecular circuit dysfunction to
disease: case studies in epilepsy, traumatic brain injury, and Alzheimer’s dis-
ease. Neuroscientist 22, 295e312.
Firat, K., Niels, B., Mark, A.V.B., Huub, J.M.D.G., Alia, A., 2011. Prospects of magnetic
resonance spectroscopy in mouse models of Alzheimers disease. Curr. Med.
Imag. Rev. 7, 80e87.
Freund, T.F., Buzsáki, G., 1996. Interneurons of the hippocampus. Hippocampus 6,
347e470.
Grouselle, D., Winsky-Sommerer, R., David, J.P., Delacourte, A., Dournaud, P.,
Epelbaum, J., 1998. Loss of somatostatin-like immunoreactivity in the frontal
cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele. Neu-
rosci. Lett. 255, 21e24.
Gueli, M.C., Taibi, G., 2013. Alzheimer’s disease: amino acid levels and brain meta-
bolic status. Neurol. Sci. 34, 1575e1579.
Hertz, L., 2013. The glutamateeglutamine (GABA) cycle: importance of late post-
natal development and potential reciprocal interactions between biosynthesis
and degradation. Front. Endocrinol. 4, 59e74.
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F.,
Cole, G., 1996. Correlative memory deficits, Ab elevation, and amyloid plaques in
transgenic mice. Science 274, 99e103.
Jo, S., Yarishkin, O., Hwang, Y.J., Chun, Y.E., Park, M., Woo, D.H., Bae, J.Y., Kim, T.,
Lee, J., Chun, H., Park, H.J., Lee, D.Y., Hong, J., Kim, H.Y., Oh, S.-J., Park, S.J., Lee, H.,
Yoon, B.-E., Kim, Y., Jeong, Y., Shim, I., Bae, Y.C., Cho, J., Kowall, N.W., Ryu, H.,
Hwang, E., Kim, D., Lee, C.J., 2014. GABA from reactive astrocytes impairs
memory in mouse models of Alzheimer’s disease. Nat. Med. 20, 886e896.
Jucker, M., Walker, L.C., 2011. Pathogenic protein seeding in Alzheimer’s disease and
other neurodegenerative disorders. Ann. Neurol. 70, 532e540.
Ke, Y., Streeter, C.C., Nassar, L.E., Sarid-Segal, O., Hennen, J., Yurgelun-Todd, D.A.,
Awad, L.A., Rendall, M.J., Gruber, S.A., Nason, A., Mudrick, M.J., Blank, S.R.,
Meyer, A.A., Knapp, C., Ciraulo, D.A., Renshaw, P.F., 2004. Frontal lobe GABA
levels in cocaine dependence: a two-dimensional, J-resolved magnetic reso-
nance spectroscopy study. Psychiatry Res. 130, 283e293.
Kesner, R.P., 2007. A behavioral analysis of dentate gyrus function. Prog. Brain Res.
163, 567e576.
Kobayashi, D.T., Chen, K.S., 2005. Behavioral phenotypes of amyloid-based geneti-
cally modified mouse models of Alzheimer’s disease. Genes Brain Behav. 4,
173e196.
Krantic, S., Isorce, N., Mechawar, N., Davoli, M.A., Vignault, E., Albuquerque, M.,
Chabot, J.G., Moyse, E., Chauvin, J.P., Aubert, I., McLaurin, J., Quirion, R., 2012.
Hippocampal GABAergic neurons are susceptible to amyloid-b toxicity in vitro
and are decreased in number in the Alzheimer’s disease TgCRND8 mouse
model. J. Alzheimers. Dis. 29, 293e308.
Lalande, J., Halley, H., Balayssac, S., Gilard, V., Déjean, S., Martino, R., Francés, B.,
Lassalle, J.M., Malet-Martino, M., 2014. 1H NMR metabolomic signatures in five
brain regions of the AbPPswe Tg2576 mouse model of Alzheimer’s disease at
four ages. J. Alzheimers. Dis. 39, 121e143.
Laschet, J., Grisar, T., Bureau, M., Guillaume, D., 1992. Characteristics of putrescine
uptake and subsequent GABA formation in primary cultured astrocytes from
normal C57BL/6J and epileptic DBA/2J mouse brain cortices. Neuroscience 48,
151e157.
Lehmann, K., Steinecke, A., Bolz, J., 2012. GABA through the ages: regulation of
cortical function and plasticity by inhibitory interneurons. Neural Plast. 2012,
1e11.
Li, Y., Sun, H., Chen, Z., Xu, H., Bu, G., Zheng, H., 2016. Implications of GABAergic
neurotransmission in Alzheimer’s disease. Front. Aging Neurosci. 8, 31e42.
Lloret, A., Badía, M.-C., Mora, N.J., Ortega, A., Pallardó, F.V., Alonso, M.-D., Atamna, H.,
Viña, J., 2008. Gender and age-dependent differences in the mitochondrial
apoptogenic pathway in Alzheimer’s disease. Free Radic. Biol. Med. 44,
2019e2025.
Lowe, S.L., Francis, P.T., Procter, A.W., Palmer, A.M., Davison, A.N., Bowen, D.M., 1988.
Gamma-aminobutyric acid concentration in brain tissue at two stages of Alz-
heimer’s disease. Brain 111, 785e799.
Maas, W.E., Laukien, F.H., Cory, D.G., 1996. Gradient, high resolution, magic angle
sample spinning nmr. J. Am. Chem. Soc. 118, 13085e13086.
Martin, D.L., Rimvall, K., 1993. Regulation of g-aminobutyric acid synthesis in the
brain. J. Neurochem. 60, 395e407.
U. Roy et al. / Neurobiology of Aging 62 (2018) 168e179 179Massucci, F.A., DiNuzzo, M., Giove, F., Maraviglia, B., Castillo, I.P., Marinari, E.,
Martino, A.D., 2013. Energy metabolism and glutamate-glutamine cycle in the
brain: a stoichiometric modeling perspective. BMC Syst. Biol. 7, 103e116.
McQuail, J.A., Frazier, C.J., Bizon, J.L., 2015. Molecular aspects of age-related cognitive
decline: the role of GABA signaling. Trends Mol. Med. 21, 450e460.
Meiboom, S., Gill, D., 1958. Modified spin-echo method for measuring nuclear
relaxation times. Rev. Sci. Instrum. 29, 688e691.
Moreira, P.I., Carvalho, C., Zhu, X., Smith, M.A., Perry, G., 2010. Mitochondrial
dysfunction is a trigger of Alzheimer’s disease pathophysiology. Biochim. Bio-
phys. Acta 1802, 2e10.
Musicco, M., 2009. Gender differences in the occurrence of Alzheimer’s disease.
Funct. Neurol. 24, 89e92.
Nakamura, S., Kawamata, T., Akiguchi, I., Kameyama, M., Nakamura, N., Kimura, H.,
1990. Expression of monoamine oxidase B activity in astrocytes of senile pla-
ques. Acta Neuropathol. 80, 419e425.
Nakashiba, T., Cushman, J.D., Pelkey, K.A., Renaudineau, S., Buhl, D.L., McHugh, T.J.,
Barrera, V.R., Chittajallu, R., Iwamoto, K.S., McBain, C.J., Fanselow, M.S.,
Tonegawa, S., 2012. Young dentate granule cells mediate pattern separation,
whereas old granule cells facilitate pattern completion. Cell 149, 188e201.
Nilsen, J., Morales, A., Brinton, R.D., 2006. Medroxyprogesterone acetate exacerbates
glutamate excitotoxicity. Gynecol. Endocrinol. 22, 355e361.
Nilsen, L.H., Melø, T.M., Witter, M.P., Sonnewald, U., 2014a. Early differences in
dorsal hippocampal metabolite levels in males but not females in a transgenic
rat model of Alzheimer’s disease. Neurochem. Res. 39, 305e312.
Nilsen, L.H., Witter, M.P., Sonnewald, U., 2014b. Neuronal and astrocytic metabolism
in a transgenic rat model of Alzheimer’s disease. J. Cereb. Blood Flow Metab. 34,
906e914.
O’Gorman, R.L., Michels, L., Edden, R.A., Murdoch, J.B., Martin, E., 2011. In Vivo
Detection of GABA and glutamate with MEGA-PRESS: reproducibility and
gender effects. J. Magn. Reson. Imaging 33, 1262e1267.
Ono, K., Yamada, M., 2011. Low-n oligomers as therapeutic targets of Alzheimer’s
disease. J. Neurochem. 117, 19e28.
Pike, C.J., Cotman, C.W., 1993. Cultured GABA-immunoreactive neurons are resistant
to toxicity induced by b-amyloid. Neuroscience 56, 269e274.
Price, J.L., Davis, P.B., Morris, J.C., White, D.L., 1991. The distribution of tangles,
plaques and related immunohistochemical markers in healthy aging and Alz-
heimer’s disease. Neurobiol. Aging 12, 295e312.
Ramos, B., Baglietto-Vargas, D., Rio, J.C.D., Moreno-Gonzalez, I., Santa-Maria, C.,
Jimenez, S., Caballero, C., Lopez-Tellez, J.F., Khan, Z.U., Ruano, D., Gutierrez, A.,
Vitorica, J., 2006. Early neuropathology of somatostatin/NPY GABAergic cells in
the hippocampus of a PS1  APP transgenic model of Alzheimer’s disease.
Neurobiol. Aging 27, 1658e1672.
Reddy, P.H., Beal, M.F., 2008. Amyloid beta, mitochondrial dysfunction and synaptic
damage: implications for cognitive decline in aging and Alzheimer’s disease.
Trends Mol. Med. 14, 45e53.
Robert, O., Sabatier, J., Desoubzdanne, D., Lalande, J., Balayssac, S., Gilard, V.,
Martino, R., Malet-Martino, M., 2011. pH optimization for a reliable quantifi-
cation of brain tumor cell and tissue extracts with 1H NMR: focus on choline-
containing compounds and taurine. Anal. Bioanal. Chem. 399, 987e999.
Rossor, M.N., Garrett, N.J., Johnson, A.L., Mountjoy, C.Q., Roth, M., Iversen, L.L., 1982.
A post-mortem study of the cholinergic and gaba systems in senile dementia.
Brain 105, 313e330.
Samakashvili, S., Ibáñez, C., Simó, C., Gil-Bea, F.J., Winblad, B., Cedazo-Mínguez, A.,
Cifuentes, A., 2011. Analysis of chiral amino acids in cerebrospinal fluid samples
linked to different stages of Alzheimer disease. Electrophoresis 32, 2757e2764.Sanacora, G., Mason, G.F., Rothman, D.L., Behar, K.L., Hyder, F., Petroff, O.A.,
Berman, R.M., Charney, D.S., Krystal, J.H., 1999. Reduced cortical g-aminobutyric
acid levels in depressed patients determined by proton magnetic resonance
spectroscopy. Arch. Gen. Psychiatry 56, 1043e1047.
Saura, J., Luque, J.M., Cesura, A.M., Da Prada, M., Chan-Palay, V., Huber, G., Löffler, J.,
Gray, J., Richards, J.G., 1994. Increased activity of monoamine oxidase-B in
plaque-associated astrocytes in Alzheimer brain demonstrated by quantitative
enzyme autoradiography using 3H-lazabemide. Neurobiol. Aging 15,
S120eS121.
Seidl, R., Cairns, N., Singewald, N., Kaehler, S.T., Lubec, G., 2001. Differences between
GABA levels in Alzheimer’s disease and Down syndrome with Alzheimer-like
neuropathology. Naunyn Schmiedebergs Arch. Pharmacol. 363, 139e145.
Simmons, M.L., Frondoza, C.G., Coyle, J.T., 1991. Immunocytochemical localization of
N-acetyl-aspartate with monoclonal antibodies. Neuroscience 45, 37e45.
Spillane, J.A., White, P., Goodhardt, M.J., Flack, R.H.A., Bowen, D.M., Davison, A.N.,
1977. Selective vulnerability of neurones in organic dementia. Nature 266,
558e559.
Stanley, D.P., Shetty, A.K., 2004. Aging in the rat hippocampus is associated with
widespread reductions in the number of glutamate decarboxylase-67 positive
interneurons but not interneuron degeneration. J. Neurochem. 89, 204e216.
Sun, B., Halabisky, B., Zhou, Y., Palop, J.J., Yu, G., Mucke, L., Gan, L., 2009. Imbalance
between GABAergic and glutamatergic transmission impairs adult neurogenesis
in an animal model of Alzheimer’s disease. Cell Stem Cell 5, 624e633.
Takahashi, H., Brasnjevic, I., Rutten, B.P.F., Van Der Kolk, N., Perl, D.P., Bouras, C.,
Steinbusch, H.W.M., Schmitz, C., Hof, P.R., Dickstein, D.L., 2010. Hippocampal
interneuron loss in an APP/PS1 double mutant mouse and in Alzheimer’s dis-
ease. Brain Struct. Func. 214, 145e160.
Takeuchi, A., Irizarry, M.C., Duff, K., Saido, T.C., Hsiao Ashe, K., Hasegawa, M.,
Mann, D.M.A., Hyman, B.T., Iwatsubo, T., 2000. Age-related amyloid beta
deposition in transgenic mice overexpressing both Alzheimer mutant presenilin
1 and amyloid beta precursor protein Swedish mutant is not associated with
global neuronal loss. Am. J. Pathol. 157, 331e339.
Terry, R.D., Masliah, E., Salmon, D.P., Butters, N., DeTeresa, R., Hill, R., Hansen, L.A.,
Katzman, R., 1991. Physical basis of cognitive alterations in Alzheimer’s disease:
synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30,
572e580.
Tu, S., Okamoto, S.-I., Lipton, S.A., Xu, H., 2014. Oligomeric Ab-induced synaptic
dysfunction in Alzheimer’s disease. Mol. Neurodegener. 9, 48.
van Duijn, S., Nabuurs, R.J., van Duinen, S.G., Natté, R., van Buchem, M.A., Alia, A.,
2013. Longitudinal monitoring of sex-related in vivo metabolic changes in the
brain of Alzheimer’s disease transgenic mouse using magnetic resonance
spectroscopy. J. Alzheimers Dis. 34, 1051e1059.
Viña, J., Lloret, A., 2010. Why women have more Alzheimer’s disease than men:
gender and mitochondrial toxicity of amyloid-beta peptide. J. Alzheimers Dis.
20, 527e533.
Yarishkin, O., Lee, J., Jo, S., Hwang, E.M., Lee, C.J., 2015. Disinhibitory action of
astrocytic GABA at the perforant path to dentate gyrus granule neuron synapse
reverses to inhibitory in Alzheimer’s disease model. Exp. Neurobiol. 24,
211e218.
Zheng, H., Xu, H., Uljon, S.N., Gross, R., Hardy, K., Gaynor, J., Lafrancois, J.,
Simpkins, J., Refolo, L.M., Petanceska, S., Wang, R., Duff, K., 2002. Modulation of
Ab peptides by estrogen in mouse models. J. Neurochem. 80, 191e196.
Zimmer, R., Teelken, A.W., Trieling, W.B., Weber, W., Weihmayr, T., Lauter, H., 1984.
G-aminobutyric acid and homovanillic acid concentration in the csf of patients
with senile dementia of Alzheimer’s type. Arch. Neurol. 41, 602e604.
